Vyliq, formerly known as relecabtagene autotempa, represents a significant step in the approach of relapsed or refractory aggressive large B-cell lymphoma (LBCL). This unique therapy utilizes a modified CAR-T cell https://vyliq549405.newsyblog.com/1325724/vyliq-a-deep-examination-into-the-new-treatment